Clinical trials: Staphylococcus Aureus
- Condition Staphylococcus Aureus
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Nasal Decolonization of Staphylococcus Aureus
A Study to Evaluate the Safety and Efficacy of 3% LTX-109 for Nasal Decolonisation of Staphylococcus
A Phase I/IIa, double-blind, placebo-controlled, randomised study designed to evaluate the safety, tolerability, exploratory efficacy and exposure of LTX-109 administered topically to the anterior nares in subjects with…
- Trial name
- NCT04767321
- Testing
- LTX-109 gel, 3% w/w
- Where
- Sweden
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Pharma Holdings AS
Staphylococcal Infections, Cardiovascular Diseases
StaphVAX in Cardiovascular Surgery Patients
S. aureus is the most common pathogen encountered in infection associated with cardiovascular surgery. StaphVAX® is a bivalent S.
- Conditions
- Staphylococcal Infections, Cardiovascular Diseases, Cardiovascular Surgical Procedures
- Trial name
- NCT00211913
- Testing
- S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Nabi Biopharmaceuticals
Healthy Volunteers, Anti-Bacterial Agents
A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of N-Rephasin® SAL200 in Healthy Male Volunteers
The Objectives of this study is to evaluate the safety, pharmacokinetics and pharmacodynamics of single dose of N-Rephasin® SAL200 in healthy male subjects.
- Conditions
- Healthy Volunteers, Anti-Bacterial Agents, Methicillin-Resistant Staphylococcus Aureus
- Trial name
- NCT01855048
- Testing
- N-Rephasin® SAL200
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Intron Biotechnology, Inc.
Staphylococcus (S.) Aureus Infection
A First in Human Trial to Assess the Safety and Immunogenicity of LTB-SA7 Vaccine Against Staphylococcus Aureus.
In this study, the candidate vaccine LTB-SA7 will be tested for safety and immunogenicity in healthy adults.
- Trial name
- LTBSA701 (NCT06719219)
- Testing
- LTB-SA7
- Where
- United States
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- LimmaTech Biologics AG
Staphylococcal Infections
V710 First-In-Man (FIM) Study (V710-001)
This is a randomized, Multicenter, double-blind (subject, investigator, and Merck Research Laboratories (MRL) clinical personnel directly involved in the study), placebo-controlled, dose-ranging study in healthy adults 18 to 55…
- Trial name
- NCT00303069
- Testing
- V710
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Staphylococcus Aureus
Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization
The proposed study aims to further evaluate the safety and immunogenicity of a candidate S. aureus vaccine NDV-3A, as well as its efficacy against acquisition of S. aureus
- Trial name
- NCT03455309
- Testing
- NDV-3A
- Where
- United States
- Volunteers
- 382 people, healthy volunteers welcome
- Sponsor
- NovaDigm Therapeutics, Inc.
Staphylococcus Aureus Infection
A Clinical Study in Health Subjects to Evaluate 9MW1411 Injection
This is a Phase 1, first time in human study enrolling approximately 42 healthy adult subjects (18-45 yrs) from one study site. The purpose of this study is to evaluate the safety, tolerability and PK of MW14 in healthy adult…
- Trial name
- NCT04784312
- Testing
- 9MW1411 injection
- Where
- China
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Infections, Bacterial
Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus Aureus
This is a Phase I/IIa randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, and efficacy of Retapamulin ointment, 1% applied twice daily for 3 or 5 days to the anterior nares of healthy…
- Trial name
- NCT00539994
- Testing
- retapamulin
- Where
- 4 sites in United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Staphylococcal Infections
Safety, Tolerability, and Immunogenicity of a Single Dose of Merck 0657nI Staphylococcus Aureus Vaccine With or Without Merck Aluminum Adjuvant (V710-002)
The purpose of this study was to evaluate the safety, tolerability, and immunogenicity of the Merck 0657nI S. aureus vaccine (V710) either with or without Merck Aluminum Adjuvant (MAA).
- Trial name
- NCT01324440
- Testing
- V710 (30 µg) with MAA, V710 (30 µg) without MAA
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Nasal Decolonization of Staphylococcus Aureus
Study to Evaluate the Efficacy, Safety and Tolerability of 3% LTX-109 for Nasal Decolonisation of Staphylococcus Aureus
A Phase IIa, double-blind, placebo-controlled, randomised study designed to evaluate the efficacy, safety and tolerability of two dosing regimens with LTX-109 administered topically to the anterior nares in subjects with…
- Trial name
- NCT05889351
- Testing
- Vehicle gel, 4 + 4 applications or 4 + 2 applications, LTX-109 3% gel, 4 + 4 applications, LTX-109 3% gel, 4 + 2 applications
- Where
- Sweden
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Pharma Holdings AS
Atopic Dermatitis
Observer-Blinded Dose Escalating, Single Dose to Study Safety and Antimicrobial Efficacy of Gel vs. Placebo
A Randomized, Observer-Blinded, Vehicle Controlled, Single Dose, Dose Escalating, Single Application Within-patient Bilateral Comparison. The goal is to determine the safety and tolerability of DBI-001 Gel vs.
- Trial name
- NCT04192513
- Testing
- J. lividum
- Where
- Dominican Republic
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- DermBiont, Inc.
Staphylococcal Infections, Joint Prosthesis
StaphVAX Immunogenicity in Orthopedic Implant Patients
S. aureus is the most common pathogen involved in prosthetic joint infection. StaphVAX® is a vaccine to prevent these infections, which conjugates the purified capsular polysaccharides of S. aureus to a carrier protein.
- Trial name
- NCT00211926
- Testing
- S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Nabi Biopharmaceuticals
Staphylococcus Aureus Infection
Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects
Study to determine the efficacy, safety and tolerability of two concentrations of XF-73 nasal gel in combination with body and face washing with chlorhexidine gluconate cloths in eradicating nasal carriage of Staphylococcus…
- Trial name
- NCT02282605
- Testing
- XF-73 nasal gel, Chlorhexidine gluconate 2% topical cloths
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Destiny Pharma Plc
Staphylococcal Infections, Candidiasis
Safety and Immunogenicity Study of a Recombinant Protein Vaccine (NDV-3) Against S.Aureus and Candida
This randomized, double-blind, placebo-controlled study is a first-in-human Phase 1 study using two dose levels of an investigational vaccine directed against S. aureus and Candida.
- Trial name
- NCT01273922
- Testing
- NDV-3 investigational vaccine
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- NovaDigm Therapeutics, Inc.
Nasal Carriers MRSA
A Phase I/IIa Study to Evaluate the Safety, Tolerability and Efficacy of Topical LTX-109 in Subjects Nasally Colonized With Methicillin-resistant/-Sensitive Staphylococcus Aureus (MRSA/MSSA)
This is a pilot study conducted to evaluate the safety, local tolerability and efficacy of LTX-109(Lytixar™), a lytic peptide designed to kill bacterias quickly and efficient.
- Trial name
- NCT01158235
- Testing
- LTX-109
- Where
- Sweden
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Lytix Biopharma AS
Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)
A Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects
A Phase 1, Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects.
- Trial name
- NCT02439359
- Testing
- CF-301
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- ContraFect
Staphylococcus Aureus
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893 in Healthy Adult Subjects
This is a Phase 1, first time in human study enrolling approximately 33 healthy adult subjects (18-65 yrs) from one study site. The purpose of this study is to evaluate the safety, tolerability and PK of MEDI4893 in healthy adult…
- Trial name
- NCT01769417
- Testing
- MEDI4893
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Staphylococcal Infections
Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years
This is a first-in-human (Phase 1) and Phase 2 study of a single vaccination with one of three dose levels of an investigational vaccine against Staphylococcus aureus (SA4Ag).
- Trial name
- NCT01364571
- Testing
- SA4Ag vaccine low dose, Blood draw, Colonization swab sample
- Where
- 16 sites in United States
- Volunteers
- 456 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
Safety and Immunogenicity Study of V710 Lyophilized Formulation (V710-004)
This study is being performed to evaluate a single 60 Mcg dose of lyophilized formulation of Merck Staphylococcus aureus vaccine (V710) in healthy subjects.
- Trial name
- NCT00822757
- Testing
- Comparator: V710
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Infections, Staphylococcal
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Staphylococcal Investigational Vaccine in Healthy Adults
The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of several formulations of an investigational Staphylococcal vaccine.
- Trial name
- NCT01160172
- Testing
- Staphylococcal investigational vaccine GSK2392103A, Staphylococcal investigational vaccine GSK2392105A, Staphylococcal investigational vaccine GSK2392106A
- Where
- Belgium
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline